Axsome Therapeutics, Inc. (AXSM) News
Filter AXSM News Items
AXSM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AXSM News Highlights
- For AXSM, its 30 day story count is now at 15.
- Over the past 21 days, the trend for AXSM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about AXSM are DRUG, CNS and AXS.
Latest AXSM News From Around the Web
Below are the latest news stories about AXSOME THERAPEUTICS INC that investors may wish to consider to help them evaluate AXSM as an investment opportunity.
2 Bear Market Defying Stocks to Buy in MayThis group of companies includes Sanofi (NASDAQ: SNY) and Axsome Therapeutics (NASDAQ: AXSM). France-based Sanofi is a biotech giant with a diversified portfolio of medicines and vaccines, although it is perhaps best known for being one of the leaders in the insulin market. The company grabbed headlines in this space earlier this year when it decided to cut the price of its top-prescribed insulin product, Lantus, by 78% and limit out-of-pocket costs to $35. |
2 Unstoppable Growth Stocks to Buy in 2023 and BeyondThe biotech industry's biggest names tend to receive most of the attention. It may only take a few positive clinical updates, regulatory decisions, or a single successful drug to turn a biotech company's fortunes around. It grew from a $4 billion company into a $59 billion company thanks to the success of its coronavirus vaccine. |
Is a Victory for Its Rivals Bad News for Axsome Therapeutics?AXS-05 met its primary and secondary goals in the study, and importantly, looked to be on track to enter the market with zero competition. The Food and Drug Administration (FDA) recently gave a different drug the nod as the first approved treatment for agitation linked to Alzheimer's disease: Otsuka Pharmaceutical and Lundbeck's Rexulti, a drug already being marketed for major depressive disorder. |
Analysts Just Made A Substantial Upgrade To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) ForecastsAxsome Therapeutics, Inc. ( NASDAQ:AXSM ) shareholders will have a reason to smile today, with the analysts making... |
3 Growth Stocks to Buy and HoldThe stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling. In that spirit, we asked three Motley Fool contributors to discuss buy-and-hold-worthy growth stocks. Read on to find out why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). |
2 Magnificent Growth Stocks You Can Buy With $150 Right NowOver the past few years, new investors have learned the hard way that investing in growth stocks can be highly unpredictable. You may remember the Nasdaq Composite, which contains heaps of growth stocks, rose 21% in 2021, only to collapse 33% in 2022. Giant market swings like the one recently experienced may lead you to believe that growth stock investing is an endeavor only suited to Wall Street professionals, but this is not the case. |
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?Axsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two products: Sunosi, a sleep disorder drug it acquired from Jazz Pharmaceuticals; and Auvelity, an antidepressant it developed in house. Thanks to those successes, Axsome shares soared more than 100% in 2022, even amid the broader bear market. |
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume RisesAxsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains. |
Q1 2023 Axsome Therapeutics Inc Earnings CallQ1 2023 Axsome Therapeutics Inc Earnings Call |
Axsome Therapeutics Clocks Better Than Expected Q1 Sales, Depression Drug Sees Improved CoverageAxsome Therapeutics Inc (NASDAQ: AXSM) reported Q1 revenue of $94.6 million, consisting of net product sales of $28.6 million, license revenue of $65.7 million, and royalty revenue of $0.3 million. The analysts estimated sales of $26.07 million. The company reported an EPS loss of $(0.26), beating the consensus of $(1.04). Sales from the depression drug, Auvelity were $15.7 million for the first quarter of 2023. The Q1 was the first full quarter of sales for Auvelity, launched in October 2022. A |